<- Go Home
Avalo Therapeutics, Inc.
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. Its lead asset includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
Market Cap
$42.7M
Volume
72.3K
Cash and Equivalents
$125.0M
EBITDA
-$50.0M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
-$14.9M
Profit Margin
3382.09%
52 Week High
$16.00
52 Week Low
$4.06
Dividend
N/A
Price / Book Value
0.35
Price / Earnings
-0.82
Price / Tangible Book Value
0.39
Enterprise Value
-$82.4M
Enterprise Value / EBITDA
1.66
Operating Income
-$50.3M
Return on Equity
678.24%
Return on Assets
-23.98
Cash and Short Term Investments
$125.0M
Debt
N/A
Equity
$122.6M
Revenue
$441.0K
Unlevered FCF
-$240.2M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium